Cognition Therapeutics Inc (NAS:CGTX)
$ 2.55 -0.05 (-1.92%) Market Cap: 102.15 Mil Enterprise Value: 68.51 Mil PE Ratio: 0 PB Ratio: 3.53 GF Score: 22/100

Cognition Therapeutics Inc at JMP Securities Life Sciences Conference Transcript

Jun 16, 2022 / 04:30PM GMT
Release Date Price: $1.91 (+5.52%)
Unidentified Participant

Welcome back to the next session here. It is my pleasure to introduce Lisa Ricciardi, President & CEO of Cognition Therapeutics. Thank you so much for joining us.

Lisa Ricciardi
Cognition Therapeutics, Inc. - President & CEO

Pleasure. Thanks for having me. Thank you all for coming, making it in on such a miserable day. We are public company, so please look at our forward-looking statement. If you are not familiar with Cognition, in brief, a couple of things to tell you -- age-related neurodegenerative disorders. This has been the company's focus and history.

That specifically means Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and dry age-related macular degeneration. Our scientific founder had an interest in synaptic biology -- learning and memory. That's the history of the company, and that is why we have ended up with the expertise and depths we have.

Now since today was the morning we all read about Roche, let me just say this once and I will say it later, our drug does not target A-beta

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot